Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 2,508 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal protein Clear all

Conditions: Primary Immunodeficiency
Interventions: Gadolinium For abdomen, Gadolinium For lower back, Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, Efficacy of Gammagard subcutaneously at Week 36, Efficacy of Gammagard subdermally at Week 36, Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 36, Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subdermally at Week 36; Drug
Lead sponsor: ASIS Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Westminster, California

Conditions: Hypertension
Interventions: Para-aminohippuric Acid, Angiotensin II, Norepinephrine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: Immediate weight loss, Pioglitazone, Deferred weight loss, Placebo; Behavioral · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Myeloma
Interventions: Stem Cell Transplant, Cyclophosphamide + Mesna, Melphalan, Granulocyte-colony stimulating factor; Procedure · Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Nocturnal Enuresis, Anemia, Sickle Cell
Interventions: Desmopressin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 8 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, topotecan hydrochloride, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stroke
Interventions: Alteplase, Alteplase Placebo, Aspirin, Aspirin Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 88
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more

Conditions: Malignant Melanoma, Head and Neck Cancer
Interventions: Filgrastim; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Air Pollution Toxicity
Interventions: L-carnosine, placebo; Dietary Supplement · Other
Lead sponsor: University of Louisville; Other
Eligibility: 22 Years to 65 Years
Enrollment: 299 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Graft Versus Host Disease, Lymphoma
Interventions: aldesleukin, recombinant interferon gamma, busulfan, cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy, Kidney Stone, Obesity
Interventions: Low-oxalate controlled diet, Primed, continuous intravenous infusion of 13C2-oxalate; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions: 17 B estradiol orally, 17 B estradiol; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 13 Years to 20 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Jacksonville, Florida • Philadelphia, Pennsylvania

Conditions: Sarcoma
Interventions: Gemcitabine, Docetaxel and Bevacizumab; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 4
States / cities: Albuquerque, New Mexico • Santa Fe, New Mexico

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol (CZP), Arthroscopic synovial tissue biopsy; Drug · Procedure
Lead sponsor: Nathan Wei, MD, FACP, FACR:; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Sarcoma
Interventions: Cetuximab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Congestive Heart Failure, Cardiorenal Syndrome
Interventions: nesiritide, placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hypotension
Interventions: Dopamine, Arginine Vasopressin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 24 Hours
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Prostate Neoplasms
Interventions: goserelin with dutasteride, goserelin with bicalutamide and dutasteride, goserelin with bicalutamide and dutasteride and ketoconazole; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Candidiasis
Interventions: Caspofungin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more

Conditions: Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
Interventions: Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Laboratory Biomarker Analysis, Oxaliplatin, Placebo Administration, Questionnaire Administration, Rituximab, Decitabine, Biospecimen Collection, Core Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Positron Emission Tomography, Magnetic Resonance Imaging, Central Venous Cannula Insertion, Portacath Placement, Computed Tomography, Decitabine and Cedazuridine; Dietary Supplement · Drug · Other + 2 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2033
U.S. locations: 4
States / cities: Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more

Conditions: Neuroblastoma
Interventions: filgrastim, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, isotretinoin, melphalan, topotecan hydrochloride, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 5
States / cities: San Francisco, California • Chicago, Illinois • Memphis, Tennessee + 2 more

Conditions: Down Syndrome
Interventions: Insulin glulisine, Saline; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 35 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Multiple Myeloma, Leukemia, Lymphoma
Interventions: Fludarabine, Melphalan, Umbilical Cord Blood, Rituximab, Peripheral Blood Stem Cell Infusion; Drug · Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: bicalutamide, flutamide, goserelin acetate, leuprolide acetate, SU5416, radiation therapy; Drug · Radiation
Lead sponsor: University of Chicago; Other
Eligibility: Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 3
States / cities: Chicago, Illinois • LaGrange, Illinois

Search by objective public record fields.

ASIS for GAMMAGARD in Primary Immunodeficiency

Genetic Mechanisms in Human Hypertension

Insulin Regulation of Lipolysis and Lipolysis Proteins

Autologous Transplant for Multiple Myeloma

Desmopressin for Bedwetting in Children With SCD

High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke

Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer

Nucleophilic Defense Against PM Toxicity (NEAT Trial)

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

Assessment of Endogenous Oxalate Synthesis

Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism

Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas

Nesiritide and Renal Function After the Total Artificial Heart

Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants

Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

Cellular Therapy With Cord Blood Cells

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer